Compare Stocks: FTH, ENTX, EQ, and HURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$2.83 +0.4%	$1.81	$0.91 ▼ $4.20	$139.00M	1.38	1.18 million shs	147,112 shs
EQ Equillium	$2.11 -0.7%	$2.75	$0.46 ▼ $3.54	$133.10M	1.82	627,669 shs	179,060 shs
FTH Sensei Biotherapeutics	$24.42 -0.2%	$0.00	$7.20 ▼ $37.90	$32.77M	-0.25	203,814 shs	139,986 shs
HURA TuHURA Biosciences	$2.12 -0.2%	$2.27	$0.41 ▼ $3.90	$134.68M	-0.01	1.10 million shs	39,740 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	+0.36%	-4.41%	+69.88%	+116.92%	+42.42%
EQ Equillium	-3.20%	-8.62%	-26.39%	+0.47%	+232.55%
FTH Sensei Biotherapeutics	-0.45%	-15.06%	-6.24%	+2,447,999,900.00%	+2,447,999,900.00%
HURA TuHURA Biosciences	+1.44%	-2.53%	-5.36%	-10.92%	-19.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$2.83 +0.4%	$1.81	$0.91 ▼ $4.20	$139.00M	1.38	1.18 million shs	147,112 shs
EQ Equillium	$2.11 -0.7%	$2.75	$0.46 ▼ $3.54	$133.10M	1.82	627,669 shs	179,060 shs
FTH Sensei Biotherapeutics	$24.42 -0.2%	$0.00	$7.20 ▼ $37.90	$32.77M	-0.25	203,814 shs	139,986 shs
HURA TuHURA Biosciences	$2.12 -0.2%	$2.27	$0.41 ▼ $3.90	$134.68M	-0.01	1.10 million shs	39,740 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	+0.36%	-4.41%	+69.88%	+116.92%	+42.42%
EQ Equillium	-3.20%	-8.62%	-26.39%	+0.47%	+232.55%
FTH Sensei Biotherapeutics	-0.45%	-15.06%	-6.24%	+2,447,999,900.00%	+2,447,999,900.00%
HURA TuHURA Biosciences	+1.44%	-2.53%	-5.36%	-10.92%	-19.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTX Entera Bio	2.00	Hold	$9.00	219.60% Upside
EQ Equillium	2.82	Moderate Buy	$7.57	257.99% Upside
FTH Sensei Biotherapeutics	2.83	Moderate Buy	$54.90	124.08% Upside
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	327.55% Upside

Current Analyst Ratings Breakdown

Latest FTH, ENTX, EQ, and HURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2026	FTH Sensei Biotherapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$55.00
7/31/2026	FTH Sensei Biotherapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$56.00
7/28/2026	FTH Sensei Biotherapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$60.00
7/21/2026	EQ Equillium	Clear Str Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/20/2026	FTH Sensei Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
7/17/2026	ENTX Entera Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	HURA TuHURA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	FTH Sensei Biotherapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
7/13/2026	EQ Equillium	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
7/13/2026	EQ Equillium	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/26/2026	FTH Sensei Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$57.00

(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTX Entera Bio	$40K	3,470.02	N/A	N/A	$0.29 per share	9.71
EQ Equillium	$41.10M	3.25	N/A	N/A	$0.47 per share	4.50
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$128.89 per share	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTX Entera Bio	-$11.44M	-$0.27	N/A	N/A	N/A	N/A	-83.31%	-70.83%	8/7/2026 (Estimated)
EQ Equillium	-$22.40M	-$0.32	N/A	N/A	N/A	N/A	-61.43%	-53.72%	8/13/2026 (Estimated)
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
HURA TuHURA Biosciences	-$30.05M	-$0.61	N/A	N/A	N/A	N/A	-156.12%	-105.38%	8/13/2026 (Estimated)

Latest FTH, ENTX, EQ, and HURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	EQ Equillium	-$0.05	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	N/A	N/A	N/A	N/A	N/A
8/7/2026	Q2 2026	ENTX Entera Bio	-$0.08	N/A	N/A	N/A	N/A	N/A
5/15/2026	Q1 2026	FTH Sensei Biotherapeutics	N/A	-$131.45	N/A	-$131.45	N/A	N/A
5/15/2026	Q4 2025	FTH Sensei Biotherapeutics	-$0.62	-$131.45	-$130.83	-$131.45	N/A	N/A
5/15/2026	Q1 2026	HURA TuHURA Biosciences	-$0.12	-$0.13	-$0.01	-$0.13	N/A	N/A
5/13/2026	Q1 2026	EQ Equillium	-$0.04	-$0.06	-$0.02	-$0.06	N/A	N/A
5/8/2026	Q1 2026	ENTX Entera Bio	-$0.08	-$0.07	+$0.01	$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTX Entera Bio	N/A	7.93	7.93
EQ Equillium	N/A	18.62	18.62
FTH Sensei Biotherapeutics	N/A	19.69	14.39
HURA TuHURA Biosciences	N/A	1.15	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTX Entera Bio	14.11%
EQ Equillium	27.05%
FTH Sensei Biotherapeutics	10.50%
HURA TuHURA Biosciences	0.62%

Insider Ownership

Company	Insider Ownership
ENTX Entera Bio	10.57%
EQ Equillium	17.84%
FTH Sensei Biotherapeutics	7.00%
HURA TuHURA Biosciences	6.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTX Entera Bio	20	49.29 million	44.08 million	Optionable
EQ Equillium	40	63.23 million	51.95 million	Not Optionable
FTH Sensei Biotherapeutics	40	1.34 million	1.25 million	Not Optionable
HURA TuHURA Biosciences	N/A	63.68 million	59.82 million	N/A

FTH, ENTX, EQ, and HURA Headlines

Recent News About These Companies

TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday

August 6 at 3:40 AM | marketbeat.com

TuHURA Biosciences Expands Revolving Credit Facility Utilization

July 29, 2026 | tipranks.com

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Recommendation of "Moderate Buy" from Brokerages

July 29, 2026 | americanbankingnews.com

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of "Moderate Buy" from Analysts

July 24, 2026 | marketbeat.com

TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

July 22, 2026 | prnewswire.com

TuHURA Biosciences (NASDAQ:HURA) Stock Price Down 1.3% - Time to Sell?

July 22, 2026 | marketbeat.com

TuHURA Biosciences Expands Use of Revolving Credit Facility

July 7, 2026 | tipranks.com

TuHURA Biosciences, Inc.: TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets ...

June 16, 2026 | finanznachrichten.de

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood ...

June 15, 2026 | finance.yahoo.com

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

June 15, 2026 | prnewswire.com

TuHURA Biosciences Draws on New $50M Credit Facility

May 29, 2026 | tipranks.com

HURA: Refining TBS-2025 development plan

May 26, 2026 | msn.com

TuHURA Biosciences, Inc.: TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 16, 2026 | finanznachrichten.de

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 15, 2026 | prnewswire.com

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

May 12, 2026 | prnewswire.com

Citizens Initiates Coverage of TuHURA Biosciences (HURA) with Market Outperform Recommendation

April 28, 2026 | msn.com

TuHURA Biosciences Secures $50 Million Credit Facility

April 22, 2026 | tipranks.com

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

April 22, 2026 | prnewswire.com

Why TuHURA Biosciences, Inc.’s (HURA) Stock Is Down 5.48%

April 20, 2026 | aaii.comA

Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?

April 20, 2026 | finance.yahoo.com

TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations

April 7, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

FTH, ENTX, EQ, and HURA Company Descriptions

Entera Bio NASDAQ:ENTX

$2.83 +0.01 (+0.35%)

As of 02:11 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Equillium NASDAQ:EQ

$2.10 -0.02 (-0.71%)

As of 02:11 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Sensei Biotherapeutics NASDAQ:FTH

$24.42 -0.06 (-0.25%)

As of 02:11 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

TuHURA Biosciences NASDAQ:HURA

$2.12 -0.01 (-0.24%)

As of 02:11 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FTH, ENTX, EQ, and HURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FTH, ENTX, EQ, and HURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FTH, ENTX, EQ, and HURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FTH, ENTX, EQ, and HURA Company Descriptions

Entera Bio NASDAQ:ENTX

Equillium NASDAQ:EQ

Sensei Biotherapeutics NASDAQ:FTH

TuHURA Biosciences NASDAQ:HURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FTH, ENTX, EQ, and HURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FTH, ENTX, EQ, and HURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FTH, ENTX, EQ, and HURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FTH, ENTX, EQ, and HURA Company Descriptions

Entera Bio NASDAQ:ENTX

Equillium NASDAQ:EQ

Sensei Biotherapeutics NASDAQ:FTH

TuHURA Biosciences NASDAQ:HURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools